Amplia Therapeutics Ltd has released a press release.
Amplia Completes Single Dose Study of AMP945
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Initiates Multiple Dose Study of AMP945
- Investor Update - February 2021
- Quarterly Activities and Cashflow Reports - Dec 2020 Qtr
- Amplia Receives $0.53m R&D Tax Incentive
- Appendix 4D and Financial Report Half Year Ended 30 Sep 2020
Later from Amplia Therapeutics
- Amplia and Garvan Institute Enter Collaboration Agreement
- Amplia Completes Dosing in Phase 1 Clinical Study of AMP945
- ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH
- Quarterly Report and Shareholder Update
- Preclinical Data Support Developmnt AMP945 Pancreatic Cancer
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics